Cargando…
FBW7 mutations mediate resistance of colorectal cancer to targeted therapies by blocking Mcl-1 degradation
Colorectal cancer (CRC), the second leading cause of cancer-related deaths in the US, has been treated with targeted therapies. However, the mechanisms of differential responses and resistance of CRCs to targeted therapies are not well understood. In this study, we found that genetic alterations of...
Autores principales: | Tong, Jingshan, Tan, Shuai, Zou, Fangdong, Yu, Jian, Zhang, Lin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5226932/ https://www.ncbi.nlm.nih.gov/pubmed/27399335 http://dx.doi.org/10.1038/onc.2016.247 |
Ejemplares similares
-
Trametinib potentiates TRAIL‐induced apoptosis via FBW7‐dependent Mcl‐1 degradation in colorectal cancer cells
por: Lin, Lin, et al.
Publicado: (2020) -
SCF(Fbw7) Regulates Cellular Apoptosis By Targeting Mcl-1 for Ubiquitination and Destruction
por: Inuzuka, Hiroyuki, et al.
Publicado: (2011) -
Mcl‐1 inhibition overcomes BET inhibitor resistance induced by low FBW7 expression in breast cancer
por: Wang, Xu, et al.
Publicado: (2022) -
FBW7 in hematological tumors
por: Zhu, Qiaojuan, et al.
Publicado: (2020) -
Fbw7 dimerization determines the specificity and robustness of substrate degradation
por: Welcker, Markus, et al.
Publicado: (2013)